Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of GP30101 vs Prezista in Healthy Volunteers
NCT04268472Phase 1Completed
- Sponsor
- Geropharm
- Start
- Jun 2019
- Primary completion
- Sep 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of GP-30101 in human immunodeficiency virus infection (HIV) (2 arms), sponsored by Geropharm. Primary endpoints: Maximum Plasma Concentration and Area Under the Concentration-Time Curve from Time Zero to Last Quantifiable Concentration. Started Jun 2019; status: completed.
02
Drugs
GP-30101
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT04268472.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04268472.